They don't have any effectiveness data, they looked at biomarkers in CSF. There's lots of interesting work being done on second generation secretase inhibitors, but they are years away.
I actually don't think those side effects are too terrible considering the disease. AD is an atrocious death sentence. People seem to be OK with heavy side effects for cancer, but not AD and I think that is a little unfair.
LLY did take a big chance moving to a large ph 3 with only CSF data. I don't think safety is what is going to kill this drug. There is really no indication that it works.
I do think this trial, along with the bapineuzimab trials, will be enormously beneficial for research purposes. I think the AD community and industry will get enough info from those trials to really be able to develop better hyotheses and a new generation of drugs.
Market Data 
Markets 
AI
